Juan P. Serrate, DVM

$AZN With Serena-4 behind, all eyes on Avanzar. Prospective validation of the TROP2 biomarker. Not massive expectations (biomarker added after Tropion data and goes against Keytruda). Best case would be PFS hit in ITT and meaningful effect in biomarker population. OS should be mature enough.

$ABVX this is really good. 40% delta Plans to submit NDA

CRL is more likely than approval at this point. Expect it after market close. $REPL https://t.co/fMeDKjTtT3